For researchers and chemists engaged in pharmaceutical R&D, a thorough understanding of chemical intermediates like 5-Chloro-2-nitroaniline (CAS: 1635-61-6) is crucial. This compound, a yellow to orange powder, possesses specific properties that dictate its synthesis, handling, and ultimate application in creating advanced pharmaceutical agents.

The physical form of 5-Chloro-2-nitroaniline as a powder, with a melting point typically around 125-129°C (dec.), indicates it is a solid at room temperature. This physical state influences how it is stored, transported, and utilized in laboratory settings. Proper storage, often in a tightly closed container in a cool, dry, and well-ventilated area, is recommended to maintain its integrity and prevent degradation, as advised by safety data sheets.

The synthesis of 5-Chloro-2-nitroaniline, as previously mentioned, involves controlled chemical reactions, emphasizing the need for precision and safety protocols. For R&D professionals, understanding these synthesis routes can provide insight into potential impurities and quality considerations. When purchasing, ensuring the material has undergone robust quality control measures is paramount.

Handling 5-Chloro-2-nitroaniline requires adherence to standard laboratory safety practices for chemical compounds. This includes wearing appropriate personal protective equipment (PPE) such as gloves, eye protection, and lab coats. Its classification involves hazard statements that necessitate careful handling to avoid exposure. Information regarding its toxicity and environmental impact should always be consulted through the Material Safety Data Sheet (MSDS) provided by the supplier.

For those looking to buy 5-Chloro-2-nitroaniline for their research, it is important to source from suppliers who provide comprehensive product information, including safety data. This ensures that your R&D activities are conducted safely and efficiently. As a key pharmaceutical intermediate, its proper management and use are integral to the success of your drug development projects.